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Charles Dickens, Coach K, Pogo, and the recent
history and future of vascular surgery
Bruce A. Perler, MD, MBA, Baltimore, MdIt is hard forme to believe that it has been 24 years since
I attended my first meeting of the Southern Association for
Vascular Surgery, as a guest, in Cerromar Beach, Puerto
Rico. I remember that meeting as if it was yesterday. I was
struck by how friendly everyone was, famous surgeons
whose names I had only read in journals went out of their
way to introduce themselves and say hello, the papers were
terrific, and the venue was not bad either. I decided then
and there that I had to get into this club! Fortunately, I was
elected tomembership a couple years later. However, never
then, or at any time since did I ever expect to be standing
here today as the President of this remarkable organization.
There is no greater reward in academic medicine then to be
recognized and respected by one’s peers, and when I con-
sider the 33 vascular surgeons who have precededme in this
office, I am truly humbled, and I thank you sincerely for this
wonderful honor. I would not be standing here today
without the help and support of many, many people, too
numerous to mention individually, but especially my fam-
ily: my professional, as well as my nuclear, family.
I have been privileged to spend my entire career at one
incredible institution, Johns Hopkins, and to work with so
many amazing people. To my partners, past and present,
and our Fellows, thank you for your support, your profes-
sionalism, and your friendship. We have been blessed with
two beautiful children who are quickly becoming an out-
standing young man and woman. Since I have spent most
of my waking hours as a surgeon, and not as a father or
husband, my bride, Patti, deserves all the credit for these
terrific kids. I love you all very, very much.
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1286We have experienced a most remarkable recent history
in vascular surgery and are facing rapidly changing, and
perhaps tumultuous, times ahead in our health care system,
and certainly in the practice of vascular and endovascular
surgery. A British author, a college basketball coach, and a
cartoon character. What in the world do they have to do
with vascular surgery? Well, if you will allow me some
license, I hope to show you that each of them, through
their social commentary, is in fact related to the recent
history and future of our specialty.
CHARLES DICKENS
Charles John Huffam Dickens was born in 1812 in
Plymouth, Hampshire England, the second of eight chil-
dren. By all accounts he was the most popular English
novelist of the Victorian era, as well as a social activist.
During his 58 years, he wrote 33 short stories, three non-
fiction works, and 33 novels. His novels were such classics:
Oliver Twist, David Copperfield, A Christmas Carol, and
many others. He was the most popular English novelist of
the Victorian era and in fact, many of his books have never
gone out of print. His most significant work, in my view,
was one of his two historical novels, A Tale of Two Cities.1
A Tale of Two Cities is the story of Paris and London in
the years leading up to and including the French Revolu-
tion. Life was the best or the worst it could be, depending
upon one’s social standing. This book contains some of the
most memorable lines in the history of English literature.
Just consider the first paragraph of Chapter 1:
It was the best of times, it was the worst of times
It was the age of wisdom, it was the age of foolishness
It was the spring of hope, it was the winter of despair
We had everything before us, we had nothing before us.
In many respects, these words describe the recent history of
vascular surgery as well.
Our patients, the elderly are the fastest growing seg-
ment of the population. Over the next decade, the number
of individuals over the age of 65 will increase by 50%. By
2030, one in five Americans, 70 million, will be age 65 or
older.2,3 In fact the greatest increase will be among our
oldest elderly, those over the age of 75, in whom arterial
disease predominates (Fig). Vascular surgery is a growth
area in medical practice. It is the spring of hope!
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cal operations.4 It has been estimated that by 2020 we will
perform from 1.0 million to 1.8 million procedures.4,5 We
had everything before us!
Unfortunately, vascular surgical manpower is not keep-
ing pace with these demographic needs. In the state of
Maryland, a microcosm of the country as a whole, today
there is less than one vascular surgeon per 100,000 resi-
dents. There are currently 16 counties in the state with a
combined population of 1.3 million without a vascular
surgeon. Furthermore, 40% of practicing vascular surgeons
in the state are over the age of 55; that is, nearly the age of
retirement.6 For many patients with vascular disease, it is
the winter of despair.
But, the law of supply and demand has a positive side.
Vascular surgical salaries reflect this critical need. A recent
report noted that themedian salary for a vascular surgeon in
the United States in 2009 was $330,000. Including bo-
nuses and fringe benefits themedian compensation package
was nearly $450,000.7 The median starting salary was
nearly $260,000.7 For many in our specialty, especially our
graduating Fellows, it is the best of times.
Coincident with this demographic evolution has been
technological revolution. Historically, the majority of vas-
cular surgical procedures were open operations. In the
relatively uncommon situation where a catheter-based in-
tervention was indicated, we were more than happy to refer
that patient to our colleagues, primarily in interventional
radiology. The patients received the most appropriate care,
we peacefully co-existed with our Radiology colleagues, the
systemworked. It was the best of times. But the endovascular
revolution changed everything. It was a perfect storm! And,
for several years during this transition, it was the worst of
times.
The growth of endovascular therapy marked an espe-
cially difficult and uncertain period in the history of vascular
surgery. While today, as our memories fade, we may think
that the transition of our specialty was smooth and seam-
less, it was anything like that. Suddenly, Interventional
Radiologists were transitioning from a service-oriented spe-
cialty to patient care providers, and in many communities
Fig. Growth in elderly population in the United States (Source:
U.S. Census Bureau).establishing their own clinics and outpatient practices. Car-diologists suddenly discovered the peripheral circulation!
Endovascular therapy represented a real threat to the very
existence of our specialty! We had nothing before us.
The response of our leadership was mixed. Some of our
thought leaders believed that this expansion of catheter-
based therapy was a passing fad, to be ignored, and that we
should continue to do what we were trained to do; namely,
open surgery.8 In hindsight, this attitude clearly was the age
of foolishness.
Others saw things very, very differently. They believed
that endovascular therapy represented a remarkable ad-
vance in patient care that we must embrace.9 It was the age
of wisdom.
COACH K
This brings me to my second protagonist, Coach K,
Mike Krzyzewski, the head basketball coach of my alma
mater, Duke University. The son of Polish immigrants, his
father a fireman in Chicago, he graduated from West Point
where he played basketball under Coach Bobby Knight.
After serving his military commitment he returned to West
Point where he was head coach for 5 years, before coming
to Duke in 1980. During the last 29 years at Duke he has
recorded 760 victories (833 total), 11 ACC tournament
championships, 26 NCAA tournament bids, 71 NCAA
tournament victories, 10 final four appearances, and three
national championships, and an Olympic gold medal with
the USA basketball team. Eight of his players have gone on
to become head coaches at major universities. Throughout
these three decades of success, he has never had an NCAA
violation, not even a single investigation.
But I include Coach K not for his unparalleled success
on the court, but rather because of his contributions off the
court. Krzyzeweski is also an Executive-in-Residence at
the Fuqua/Coach K Center on Leadership and Ethics at
the Fuqua School of Business at Duke, which he helped
establish. He is a widely sought after motivational speaker
at leadership and Fortune 500 company business confer-
ences around the country and has now authored six books
with significant focus on his principles of leadership.
His first book is entitled: Leading with the Heart. Coach
K’s Successful Strategies for Basketball, Business, and Life.10
In this book Coach K presents his formula for dealing with
difficult challenges, in business, in life, as on the basketball
court. Specifically he advises that when faced with a partic-
ularly difficult challenge, one should:
TAKE RESPONSIBILITY;
COME IN WITH A GREAT GAME PLAN;
GIVE IT TIME, ATTENTION, AND COMMITMENT;
ANDFOLLOWTHROUGHWITHYOUCOMMITTMENT.
I would submit that this is exactly what we have done to
address the endovascular revolution and the threat to our
specialty, and how we must proceed in the uncertain era of
health care reform ahead.
We rejected the nihilistic philosophy of some and em-
braced this technology, and have made it out own, and we
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remade our specialty, something no other specialty has ever
done and have accomplished this in record time-absolutely
unprecedented!
Our fundamental challenge was to acquire endovascu-
lar skills. Just a few years ago, very few vascular surgeons
had endovascular expertise, and it was projected that rely-
ing just on approved vascular surgical fellowships would
produce less than 600 endo-competent vascular surgeons
by 2006.12 Therefore, our GAME PLAN included obtain-
ing endovascular training in so called “mini-fellowships,”
nonaccredited endovascular training programs, ranging
from a fewweeks to a few-months in duration. Graduates of
these programs returned home and trained their partners
and their fellows. Beginning with nine mini-fellowship
programs in 2000, it was estimated that by 2006 more
than 1600 endo-competent vascular surgeons would be
trained,12 and we succeeded. Last year, 80% of vascular
surgeons taking the recertification examination were prac-
ticing endovascular therapy.13 We also incorporated endo-
vascular case requirements into our fellowship training and
added a year resulting in the 5  2 tract.14
The results speak for themselves. From 2001 to 2007,
the mean number of cases performed by graduating vascu-
lar surgery fellows nearly doubled, from 298 to 519 (Table
I). This reflected a 442% increase in the number of endo-
vascular cases, while our trainees also experienced a 7%
increase in the number of open vascular surgical cases.15
Coach K’s second book is entitled Five-Point Play.16
It’s about the 2001Duke national basketball championship
team. It talks about the fingers of a hand, as a metaphor for
a basketball team, but in fact, a metaphor for any team or
organization, or even a surgical specialty facing difficult
challenges. Krzyzewski points out that a finger is remark-
ably agile and can do lots of things, and pretty well, but in
reality, each finger is not that strong, and is limited in what
it can accomplish. However, if all five fingers come together
and make a fist, the strength of that hand, the power of
those five fingers, is so much greater than the sum of its
components.
Vascular surgery is one of the smallest specialties in
medicine. In 2007, there were 2610 active vascular sur-
geons in the United States-the smallest of the 36 major
specialties recognized by the Association of AmericanMed-
ical Colleges (AAMC) (Table II).17 To put this in perspec-
tive, there were 104,904 internists, 103,315 family practi-
tioners, and 21,511 cardiologists (Table II).17 And just as a
Table I. Vascular fellows caseload: 2001-2007a
2001 2002
Open 234.7 233.9
Endovascular diagnostic 22.2 43.1
Endovascular therapeutic 41.5 58.9
Total 298.3 335.9
aMean (Reference 21).finger, our small numbers limit our strength. But, when wecome together and speak as one specialty, like a hand in Five
Point Play, our strength is magnified several-fold, and there
is nothing we cannot accomplish, and that is exactly what
we have done, and how we must act in the coming era of
health care reform.
We have achieved a record of accomplishment un-
equaled by other specialties that dwarf us in terms of
numbers and monetary resources. Our small specialty,
through the Society for Vascular Surgery (SVS), led a
coalition that championed passage of the SAAVE Act to
provide free AAA screening for new Medicare beneficiaries
that will literally save thousands of lives; we have pioneered
the use of simulators in surgical training; and we are leading
3 2004 2005 2006 2007
.2 242.5 245.1 252.6 250.1
.6 86.0 100.4 113.1 104.7
.2 100.7 125.7 149.8 164.4
.0 430.2 471.3 515.6 519.2
Table II. Number of physicians in practice in USA
(2007) (Source: AAMC, Reference 17)
Allergy and immunology 4222
Anatomic/Clinical Pathology 15,668
Anesthesiology 38,724
Cardiovascular Disease 21,511
Child/Adolescent Psychiatry 7312
Dermatology 10,390
Emergency Medicine 30,742
Endocrinology 5448
Family Medicine 103,315
Gastroenterology 12,086
General Surgery 27,769
Geriatric Medicine 3769
Hematology/Oncology 11,802
Infectious Disease 6424
Internal Medicine 104,904
Neonatal/Perinatal Medicine 4054
Nephrology 7550
Neurologic Surgery 4921
Neurology 12,620
Obstetrics/Gynecology 39,869
Ophthalmology 17,846
Orthopedic Surgery 20,032
Otolaryngology 9,220
Pediatrics 54,061
Physical Medicine/Rehabilitation 8048
Plastic surgery 6671
Preventive medicine 7084
Psychiatry 39,371
Pulmonary disease/critical care 11,567
Radiation oncology 4,209
Radiology-diagnostic 27,562
Rheumatology 4,568
Thoracic surgery 4,820
Urology 9916
Vascular surgery 2610200
238
61
78
378the reform of surgical training paradigms.
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and senseless contention among ourselves and came to-
gether through the Vascular Surgery Board (VSB) in the
spirit of Five Pont Play. In a span of less than 3 years, the
American Board of Surgery (ABS) recognized the Vascular
Certificate as a Primary Certificate in 200618; it recognized
the VSB as “the sole body that has authority and responsi-
bility for defining vascular surgical training, certification
standards, and examination” in 200719; and in 2008 the
ABS eliminated vascular surgery as a core component of
general surgery residency training.20 We became an inde-
pendent specialty, no longer a part of general surgery.
One impediment to recruitment into surgical special-
ties in general is the length of our training programs.
Vascular surgery had a GAME PLAN for that. As a result of
our Primary Certificate, we established the 0 5 integrated
program of vascular surgical training. From four programs
in 2007 we have grown to 17 programs offering 19 training
positions in 2009, and are attracting truly outstanding
applicants, 152 in 2009 (Table III).21 We need more 0 5
programs, but funding is an obstacle and we are going to
have to fight for it.
While health policy experts predict a shortage of at least
125,000 to 200,000 physicians in the United States by
2025 due to the aging of the population and our work-
force,22,23 and while universal health care coverage will
exacerbate this demand,22 many so called experts believe
that we have, and will continue to have, an excess number
of specialists. They believe the real deficiency is in primary
care physicians.
Furthermore, in this era of increasing pressure for
health care cost containment, it’s argued that specialists
drive up costs. In recent congressional testimony, Dr David
Goodman, Director of the Center for Health Policy Re-
search at Dartmouth advocated limiting the number of
specialists we train as a strategy to effectively slow the
growth of health care spending.24 This strategy is founded
on the argument that greater physician, and in particular
specialist, supply, does not result in better health care.23 A
recent Dartmouth study concluded that states with greater
Medicare spending and more specialists had poorer health
outcomes.25 However, this research is flawed. Specifically,
it has been demonstrated that states with higher Medicare
expenditures in fact spend less on health care overall due to
larger social burdens such as more uninsured individuals
and a greater percentage of the population living below the
poverty line. In fact when total health care spending per
capita is examined, the evidence shows that states with
Table III. 0  5 vascular surgery integrated programs
2006 2007 2008 2009
Number of positions 0 4 9 19
Number of applicants 0 49 112 152
Source: Reference 21.higher per-capita health care expenditures have better-quality health care.23 Furthermore, states with more spe-
cialists have better health care. We do have a positive
impact!
The Balanced Budget Act of 1997 limits Medicare
funding for additional trainees in graduate medical educa-
tion.26 In recent congressional testimony, Dr Fitzhugh
Mullan, Professor ofMedicine andHealth Policy at George
Washington University argued that Medicare graduate
medical education funding should be utilized as a strategy
to influence the physician workforce distribution in this
country, and in particular to increase the number of primary
care physicians at the expense of specialists.27
To attract medical students to primary care and away
from higher paying specialties, the Medicare Payment Ad-
visory Commission has recommended an increase of up to
10% in payment for primary care services, to be offset by a
reduction in payments to specialty physicians,28 and this
recommendation has been debated in Congress as part of
health care reform.
A Massachusetts health care Commission has recom-
mended that the payment system in the state be changed
from a fee-for-service to a capitation model, and specifically
argued that the current system “results in specialists such as
surgeons and cardiologists earning substantially more than
primary care doctors, contributing to a shortage of these
doctors.”29 It is clear who will have the bull’s-eye on their
backs as our healthcare system continues to evolve!
However, our patients, the elderly, are most pro-
foundly threatened by health care reform and proposed
cuts in Medicare. In 2008 we spent $462 billion on 45
million Medicare beneficiaries, including $8 billion on the
treatment of 12million beneficiaries with peripheral arterial
disease,30,31 and it is projected that the system will become
insolvent in 7 years.32 Even the Congressional Budget
Office (CBO) has recently concluded that these proposed
Medicare cuts will limit seniors’ access to health care.33
Well my colleagues, we can be fearful and depressed, we
can be frustrated and angry, and we can assume it is the
winter of despair, or we can follow Coach K’s admonition
and “TAKERESPONSIBILITY.” And that leads me tomy
final protagonist: Pogo.
POGO
Pogo was the central character of a comic strip created
by Walter Kelly that ran from 1948 through 1975. It was
set in the heart of the region of the Southern Association for
Vascular Surgery, Okefenokee Swamp in Georgia. Pogo
engaged in political and social satire through the adven-
tures of its comical animal characters, which were portrayed
in a good-natured way to reflect the spectrum of human
nature, and with wit and physical humor so as to appeal to
both adults and children.
In one notable episode, from Earth Day, 1971, Pogo
and Porkypine come upon a once beautiful forest that had
been littered, and Pogo utters perhaps the most quoted line
of the nearly 30-year history of the comic strip. He says,
“Yep son, we have met the enemy and he is us.”
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are a tiny minority of the health care system, a spec in the
health care universe, and we are not responsible for the
impending financial collapse of Medicare, but we are one of
the litterers, we do contribute to the problem, and there-
fore we can be a positive force in reform by doing what we
do best-by leading by example!
Whether we like it or not, whether we want to admit it
or not, we are all engaged in the business of medicine, and
a fundamental component of that business today is direct-
to-consumer advertising. In fact, theUnited States is one of
only two countries in the world that permits direct-to-
consumer medical advertising, and New Zealand is trying
to do away with it. While this historically exclusively in-
volved pharmaceuticals, that changed during a Dallas
Cowboys-New York Jets football game in November, 2007,
when a commercial appeared for the Cypher drug-eluting
coronary stent, and now other medical devices are also
being marketed directly to the consumer.34 In 2005, phar-
maceutical companies spent $4.1 billion on television and
internet advertising. Medical device manufacturers spent
$116 million in 2005 but this had increased to $191
million by 2007.35
In an era of increasing competition for patients and
clinical revenue, the medical community has also pursued
aggressive marketing strategies, not only through paid ad-
vertisements, but also more subtly through press releases
and stories in the lay press about our latest techniques.
Many of us do it. It is not my intent to condemnmarketing-it
does create a more informed patient population. But, there
must be truth in advertising! What concerns me, what
makes us the “enemy” in Pogo’s world, is that at times we
have exaggerated the “promise” of new technologies as
proven therapy in these marketing efforts, and this is
wrong.
In a recent analysis of 200 research press releases from
academic medical centers, 29% were found to overstate the
significance of the research findings.36 This is a particular
concern in the arena of endovascular therapy.
Consider one early example. In the late 1980s the Food
and Drug Administration, based on a series of 219 patients
with no long-term follow-up, approved the hot tip laser as
a means of recanalizing femoral-popliteal occlusive disease.
This was high tech, it was star wars, it was exciting, and it
was ripe for strategic marketing. A near laser hysteria
gripped our world! Almost immediately hundreds of hos-
pitals acquired this technology and thousands of patients
were treated. Many institutions utilized the “promise” of
hot tip laser angioplasty in aggressive marketing campaigns.
Unfortunately, many of these ads were hyperbole and
misleading: presenting laser angioplasty as a “break-
through,” when in fact there was a paucity of reported data;
misrepresenting the mechanism of treatment which was
simply burning a channel through the occlusion, and not
“vaporizing” it in seconds; and suggesting it would replace
bypass surgery when typically only short lesions were being
successfully treated.Most importantly, hot tip laser angioplasty did not
work! At Johns Hopkins our interventional radiologists
acquired the technology and began treating patients, and
we collaborated with them. The results were terrible—a
1-year patency of 14%! In fact, it was the Southern Associ-
ation for Vascular Surgery that gave us the forum to present
our data, which helped stop this foolish clinical “experi-
ment.”37
Although our series was roundly criticized by many
laser advocates, within a couple years other institutions
corroborated our findings and laser angioplasty became a
sorry footnote in history, but a critically important lesson
for us all. It was an example of how we as a specialty, as
the tiny specialty that we are, and in fact how one group
within our tiny specialty can make a difference, and how
we must proceed in the future, of how we go from being
the “enemies” to the endovascular leaders that we are!
We must critically investigate the true potential of new
and evolving technologies, and apply them wisely in our
practices. Equally importantly, we must present the out-
comes of these evolving technologies in an accurate and
objective fashion to our patients, third party payors, and
our regulators. This new metric of “target lesion revascu-
larization” is not good enough! We are endovascular spe-
cialists and while we have mastered the technology wemust
never alter our clinical judgment or compromise our tradi-
tional standards of patient care. We have innumerable
opportunities for leadership in the area of endovascular
therapy.
Just consider femoral-popliteal occlusive disease, which
afflicts millions of our senior citizens to varying degrees.
Today, we literally have a dozen or so endovascular options
for treating this problem.We can dilate it with a balloon, or
dilate and cut it with a cutting balloon; we can add a stent
or primarily stent, with a plain old-fashioned stent, a drug-
eluting stent, a covered stent, or even a biodegradable
stent; we can cool it with cryoplasty; or we can heat it with
a laser, or we can radiate it with brachytherapy; or, we can
slice it with atherectomy. We can even do a percutaneous
bypass. It would seem that when you have a dozen disparate
ways to treat a solitary problem, we really do not knowwhat
works best. Yet every day these procedures are being per-
formed in hundreds of hospitals upon thousands of patients
across this country at significant cost to our health care
system. And if the stenosis or occlusion recurs, we try
something else, at additional cost. We cannot continue
along this path. The United States leads the world in
innovation, and discovering what works, but our health
care system has paid for any care, irrespective of quality or
outcomes.24 Outcomes are going to matter in the new
world order, and vascular surgeons must lead in this effort!
Leadership entails responsibility!
In 2008, the CBO published a 45-page white paper
recommending comparative effectiveness research,38 and
health care reform legislation includes establishment of a
Comparative Effectiveness Research Commission. It is not
a coincidence that news stories about this process have
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is Sutton’s Law—it is where the money is.
The Institute of Medicine recently identified the 100
most important issues for comparative effectiveness re-
search. Claudication was in the second quartile.39
In contrast to the United States, many countries around
the world already regulate health care delivery in this fashion.
The National Institute for Health and Clinical Excellence
(NICE) was established by the National Health Service
(NHS) in England to carry out so called “technology assess-
ments” of newprocedures, and the results of these technology
assessments determine resource allocation and beneficiary
coverage for theNHS.40 Since 2000, 159 “technology assess-
ments” have been conducted. The results of 36% have been
appealed, but only one-third of them have been upheld.40
I, as I assume many of you, am concerned about
increasing government control of health care, and its po-
tential impact on our patients, and our practices. On the
other hand, it is hard to deny the potential benefits of
comparative effectiveness research. A recent study pub-
lished in the New England Journal of Medicine noted that
only 55% of patients receive care supported by evidence-
based guidelines.41 Health care givers must play a central
role in this process. Vascular surgeons must determine how
best to treat a superficial femoral artery occlusion!
In fact, vascular surgery is already leading. For years
through the SVS we’ve been publishing Practice Guide-
lines. In 2008, well in advance of government legislation,
the SVS established a Comparative Effectiveness Task
Force to conduct research in this area. This group has
already published a comparative effectiveness policy state-
ment on behalf of vascular surgery,39 and is currently
conducting studies in the important areas of critical limb
ischemia and intermittent claudication.
Vascular surgeons, despite our small numbers, are
uniquely positioned to influence the health care debate and
political process in this country. We have direct access every
day, in our offices and on the wards, to the single most
influential voting bloc in our democracy: senior citizens.
Our patents trust us and care about our views on health
care, and they need us. Each of us every day must TAKE
RESPONSIBILITY at the grassroots level to communicate
with them, and educate them, and partner with them to
influence the structure of our health care system, and
protect their care.
Vascular surgeons must lead because I believe it is our
moral obligation to our patients. We are uniquely privi-
leged to have the opportunity to care for our senior citi-
zens, our “greatest generation.”42 They are our fathers and
mothers, our uncles and aunts, our neighbors and friends.
They are this country’s greatest asset, and they deserve our
gratitude, and our highest quality health care.
I want to tell you about one member of the “greatest
generation,” my patient Henrietta. She epitomizes my
clinical practice. She is the face of all of your practices. I
have discussed her case before in another venue, but her
story continues and it merits an update. Last week, January
12, Henrietta celebrated her 90th birthday. She is an aver-age citizen. She spent much of her adult life working in a
factory making burlap bags. She lives alone now with her
dog in a row house in East Baltimore, leading a simple and
very sedentary life. She was 84 when I met her 6 years ago.
She had a number of significant health problems, including
severe coronary artery disease, atrial fibrillation, congestive
heart failure, chronic obstructive pulmonary disease, hyper-
tension, and hyperlipidemia. She had presented to our
Emergency Department with several hours of severe abdom-
inal pain and a computerized tomographic (CT) scan revealed
a ruptured abdominal aortic aneurysm. Based upon her exten-
sive comorbidity and advanced age, I thought it would be a
challenge to get her through an emergency open repair. But,
Henrietta is alive and well today, 6 years later, having just
celebrated her 90th birthday!
In all candor, she is not alive because of any congressional
health care reform legislation. Quite honestly, she is not alive
because of the wisdomof any public health policy expert. And
she is most assuredly not alive because of any primary care
physician.Henrietta is alive andwell today because ofmodern
vascular surgery! She is alive today because a brilliant vascular
surgeon, Juan Parodi, dreamed, and believed you could actu-
ally perform aortic aneurysm repair from the groin, and he had
a GAME PLAN, and he worked hard, and made it happen.
She is alive today because many other vascular surgeons
TOOK RESPONSIBILITY and helped investigate this revo-
lutionary technique of endovascular aneurysm repair. She is
alive today because industry believed in this technology, and
in our specialty, and invested heavily in this technology and
collaborated with us in an ethical fashion and refined this
technology. She is alive today because older traditional vascu-
lar surgeons were willing to open their minds and accept this
radical change, andGAVEITTIMEANDCOMMITMENT
to work with their younger colleagues to get trained by them,
and perform these procedures with them, as we did in this
case.
Henrietta is alive today because unlike all other special-
ists who treat peripheral vascular disease, vascular surgeons
do not treat lesions- we do not treat aneurysms- we treat
patients, and we get to know our patients, and we follow
our patients long-term. So when Henrietta developed graft
migration and a type I endoleak 4 years ago, she underwent
further endovascular repair. And she is alive and well to-
day . . . . . . . . Henrietta, an average patient, a senior citi-
zen, a Medicare beneficiary, part of the “greatest genera-
tion,” the face of vascular surgery, the reason all of us get up
and go to work every day is alive and well today because the
“greatest generation” deserves our greatest care, because
what vascular surgeons do is important and innova-
tive, . . . . . . . . . . . . . . . and because we love what we do,
and our patients love us for it, and they will continue to love
and respect us for leading, for doing the right thing, and for
protecting their care in the future. It is the spring of hope.
Thank you.
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